To test this, we treated syngeneic mice containing established B16F10/pLKO or B16F10/shDRG2 tumors with anti-PD-1 antibody or negative control (isotype IgG), and we monitored the changes in tumor growth and mice survival (Fig. 5A). The gene discussed is PDCD1; the disease is neoplasm.